MyFinsight
Home
Blog
About
Contact
Download
Download image
Gross proceeds from
issuance of redeemable...
$127,336K
Proceeds from exercise of
stock options
$170K
Net cash provided by
financing activities
$124,585K
Canceled cashflow
$2,921K
Net increase in cash
and cash...
$80,090K
Canceled cashflow
$44,495K
Repurchases of common stock
$1,450K
Payments for deferred
offering cost
$1,183K
Issuance costs of
redeemable convertible...
$288K
Stock-based compensation
$2,786K
Accrued expenses and
other current...
$1,672K
Change in fair value of
redeemable convertible...
$1,526K
Payroll-related accruals
$900K
Depreciation expense
$612K
Accounts payable
$549K
Non-cash lease expense
$383K
Loss on disposal of
property and equipment
-$5K
Redemptions of short-term
investments
$5,996K
Net cash used in
operating activities
-$32,701K
Net cash (used in)
provided by investing...
-$11,794K
Canceled cashflow
$8,433K
Canceled cashflow
$5,996K
Net loss
-$39,869K
Purchases of short-term
investments
$17,001K
Gain on lease
termination
$518K
Lease liability
-$441K
Prepaid expenses and
other current assets
$186K
Interest receivable
$74K
Other non-current
assets
$38K
Other receivables
$8K
Property and equipment
$789K
Back
Back
Cash Flow
source: myfinsight.com
SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma, Inc. (SGP)